Lv1
30 积分 2024-04-20 加入
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
1小时前
待确认
Cancer incidence and mortality in China, 2022
7个月前
已完结
皖公网安备34019202002308
